FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of July 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.)
Form 20-F X Form 40-F
----- ------
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
----- -----
This Form 6-K consists of:
A press release issued by Vasogen Inc. on July 13, 2000, entitled: "Vasogen
Financing Completed":
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By ___________________________________
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: July 13, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive Glenn Neumann
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel: (905) 569-2265 fax: (905) 569-9231 tel: (905) 569-9065
www.vasogen.com e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN FINANCING COMPLETED
Toronto, Ontario (July 13, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) today
announced that it has completed its previously reported offering of 1.75 million
common shares at a price of $10.00 per share underwritten by Research Capital
Corporation. In addition, the underwriter has exercised its Over-Allotment
Option to acquire an additional 262,500 common shares at $10.00 per share.
The Company's cash position, taking into account the net proceeds of the issue,
is approximately $43 million.
Vasogen is focused on developing immune modulation therapies to
advance the treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental disease-causing
events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
